Search

Search Constraints

You searched for: Author/Creator Gluz, Oleg

Search Results

1. BRCA1‐like profile predicts benefit of tandem high dose epirubicin‐cyclophospamide‐thiotepa in high risk breast cancer patients randomized in the WSG‐AM01 trial. Issue 4 (5th May 2016)

2. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Issue 5 (May 2022)

3. Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer. Issue 22 (11th August 2020)

4. Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials. Issue 10 (11th February 2021)

5. Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial. Issue 1 (19th June 2019)

6. ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high‐risk characteristics by molecular expression profiling. Issue 3 (7th January 2019)

7. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. Issue 5 (7th May 2021)

8. Inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma. (10th December 2021)

10. The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice. Issue 5 (9th April 2020)